ID   COLO 824
AC   CVCL_1136
SY   COLO-824; Colo-824; Colo 824; COLO #824; COLO824; Colo824; Colorado 824
DR   CLO; CLO_0002577
DR   CLDB; cl870
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471347
DR   BioSample; SAMN03473374
DR   Cell_Model_Passport; SIDM00954
DR   ChEMBL-Cells; CHEMBL3308725
DR   ChEMBL-Targets; CHEMBL1075430
DR   CLS; 300463/p815_Colo-824
DR   Cosmic; 906812
DR   Cosmic-CLP; 906812
DR   DepMap; ACH-001820
DR   DSMZ; ACC-200
DR   GDSC; 906812
DR   GEO; GSM718287
DR   GEO; GSM783979
DR   GEO; GSM847249
DR   GEO; GSM847459
DR   GEO; GSM843492
DR   GEO; GSM843493
DR   GEO; GSM1669694
DR   IARC_TP53; 21245
DR   PharmacoDB; COLO824_237_2019
DR   Progenetix; CVCL_1136
DR   Wikidata; Q54814156
RX   PubMed=9892114;
RX   PubMed=20164919;
RX   PubMed=24176112;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: ~60-80 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=85.4%; Native American=0.04%; East Asian, North=1.28%; East Asian, South=0%; South Asian=0%; European, North=5.62%; European, South=7.67% (PubMed=30894373).
CC   Caution: Previously erroneously indicated as originating from a male patient, correct sex assignment from Moore G.E. in a personal communication to the authors of PubMed=9892114.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): CLS; Cosmic-CLP; DepMap; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11,12 (DepMap)
ST   CSF1PO: 10,12 (CLS; Cosmic-CLP; DSMZ; PubMed=25877200)
ST   D13S317: 11,12,13
ST   D16S539: 12,13 (DSMZ)
ST   D16S539: 13 (CLS; Cosmic-CLP; DepMap; PubMed=25877200)
ST   D18S51: 15,19
ST   D21S11: 28
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 7,7.3,8,11 (DepMap)
ST   D7S820: 7.9,8,11 (PubMed=25877200)
ST   D7S820: 8,11 (CLS; Cosmic-CLP; DSMZ)
ST   D8S1179: 12,14
ST   FGA: 22
ST   Penta D: 5,10
ST   Penta E: 7
ST   TH01: 7,9
ST   TPOX: 6,11
ST   vWA: 16
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-01-21; Version: 28
RX   PubMed=9892114; DOI=10.1002/(SICI)1098-2264(199901)24:1<87::AID-GCC13>3.0.CO;2-5;
RA   Savelyeva L., Claas A., An H., Weber R.G., Lichter P., Schwab M.;
RT   "Retention of polysomy at 9p23-24 during karyotypic evolution in human
RT   breast cancer cell line COLO 824.";
RL   Genes Chromosomes Cancer 24:87-93(1999).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).